Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8494369 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL974400 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL12921430 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL974796 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL1298159 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL31285391 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL2965074 | 0.90 | CHRM2 (0.52) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL8355491 | 0.90 | CHRM2 (0.52) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL8226507 | 0.90 | CHRM2 (0.52) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL2742462 | 0.90 | CHRM2 (0.52) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743178-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743447-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025016909-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025016906-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-23 | — | — | WO | disclosed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| CN-106536489-B | Retinoid-related orphan receptor gamma modulators and uses thereof | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-3148975-B1 | PIPERAZINE DERIVATIVES AS ROR-GAMMA MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20020052502-A1 | Cis-substituted aminocyclopropane derivative | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-05-02 | — | — | US | disclosed |
| US-20020002182-A1 | CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| EP-0973720-A1 | 2-SUBSTITUTED BENZOYL-CYCLOALKYL-1-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-01-26 | — | — | EP | disclosed |
| EP-0919553-A1 | cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998040344-A1 | 2-SUBSTITUTED BENZOYL-CYCLOALKYL-1-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-09-17 | — | — | WO | disclosed |
| US-4859680-A | Pyrimidine derivatives as antiviral compounds | MERCK & CO., INC. (US) | 1989-08-22 | — | — | US | disclosed |
| US-4617304-A | VIRICIDE; HERPES | MERCK & CO., INC. (US) | 1986-10-14 | — | — | US | disclosed |
| EP-0159264-A2 | Antiviral compounds | MERCK & CO. INC. (US) | 1985-10-23 | — | — | EP | disclosed |
| US-4408066-A | Methyl cyclopropane-1,3-dicarboxylate | ROUSSEL UCLAF (FR) | 1983-10-04 | — | — | US | disclosed |
| US-3956386-A | Cis-N,N,N',N'-tetramethylcyclopropane-1,2-dicarboxamide and use thereof | MONSANTO COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052502-A1 | Cis-substituted aminocyclopropane derivative | SLC11A2, MYD88, ARG1 | CHRM2 4587/4885CHRM4 4659/4885CHRM3 4549/4885 |
| US-20020002182-A1 | CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | PHOSPHO1, CCR2, ECH1 | CHRM2 290/4885CHRM4 440/4885CHRM3 235/4885 |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CHRM2 2757/4885CHRM4 1266/4885CHRM3 771/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | CHRM2 2757/4885CHRM4 1266/4885CHRM3 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.